Propiverine
- Generic Name
- Propiverine
- Brand Names
- Mictoryl
- Drug Type
- Small Molecule
- Chemical Formula
- C23H29NO3
- CAS Number
- 60569-19-9
- Unique Ingredient Identifier
- 468GE2241L
- Background
Propiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) .
Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the night to urinate). OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents , . Overactive bladder syndrome affects millions of elderly individuals in the United States and shows equal prevalence in men and women. The impact of OAB on quality of life is sometimes devastating, especially to elderly patients with other medical conditions .
Propiverine hydrochloride is a bladder detrusor muscle relaxant drug with dual antimuscarinic and calcium-modulating properties for the treatment of OAB .
- Indication
Indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB) . Propiverine may also be used in patients with neurogenic bladder as a result of spinal cord injury .
- Associated Conditions
- Urinary Incontinence (UI), Urinary Urgency, Increased frequency of urination
Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis
- Conditions
- Interstitial Cystitis
- Interventions
- Device: interferential current
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2019-02-19
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 40
- Registration Number
- NCT03844581
- Locations
- 🇪🇬
Faculty of physical therapy- Cairo University, Giza, Dokki, Egypt
🇪🇬Al Azhar University, Cairo, Egypt
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
- Conditions
- Overactive Bladder (OAB)
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Singapore Pte. Ltd.
- Target Recruit Count
- 5589
- Registration Number
- NCT03602508
- Locations
- 🇦🇺
Site AU10000, Sydney, Australia
🇰🇷Site KR82001, Seoul, Korea, Republic of
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
- Conditions
- Overactive Bladder (OAB)
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 649
- Registration Number
- NCT02294396
Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 437
- Registration Number
- NCT02024945
Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- Target Recruit Count
- 62
- Registration Number
- NCT01942681
- Locations
- 🇯🇵
Shinshu University Hospital, Matsumoto, Nagano, Japan
Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
- Conditions
- Neurogenic Urinary Bladder DisorderUrinary Bladder, NeurogenicBladder Disorder, NeurogenicUrinary Bladder Disorder, NeurogenicNeurogenic Bladder DisorderUrinary Bladder Neurogenic DysfunctionUrologic DiseasesOveractive Detrusor FunctionUrinary Incontinence
- Interventions
- First Posted Date
- 2012-02-10
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- APOGEPHA Arzneimittel GmbH
- Target Recruit Count
- 66
- Registration Number
- NCT01530620
Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Lee's Pharmaceutical Limited
- Target Recruit Count
- 324
- Registration Number
- NCT01512004
- Locations
- 🇨🇳
Beijing Chaoyang Hospital, Beijing, China
Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 264
- Registration Number
- NCT00903045
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2008-11-21
- Lead Sponsor
- APOGEPHA Arzneimittel GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT00795925
A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 41
- Registration Number
- NCT00646880
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.